By leveraging high-throughput proteomic profiling (Nanostring GeoMx®) and circulating tumor DNA (ctDNA) monitoring, we identify actionable targets for HAL-specific precision therapy, such as EBV-directed CAR T-cells or PD-1 blockade in combination with MYC inhibition. Here, MYC is linked to neoplasm.